Navigation Links
Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
Date:3/29/2011

ANAHEIM, Calif., March 29, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq:  QCOR) announced today that executive management will present at the Needham Healthcare Conference to be held April 5-6, 2011 at the New York Palace Hotel in New York City.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Tuesday, April 5, 2011 at 8:00 a.m. ET.

To listen to the audio web cast of the presentation during or after the event, please visit: www.questcor.com.  The replay will be available for ninety days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age.  Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Drug delivery technologies that ... essential part of the entire drug development process. ... in new vaccine delivery technologies in a bid ... skin delivery procedures. New analysis from ... though the needle-free delivery sector currently makes up ...
(Date:9/2/2014)... COSTA MESA, Calif. , Sept. 2, 2014 ... organization was just recognized as one of the ... Over the past few years, the company has ... phase clinical research, late phase global clinical development, ... the past 2 years, WCCT Global has successfully ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
Breaking Medicine Technology:Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18
... USCAP MeetingSOUTH SAN FRANCISCO, Calif., March 13 Rigel ... the enrollment of the first patient in a Phase ... patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). ... the efficacy of R788, an orally bio-available Syk kinase ...
... Phase II Study Published in The Lancet of Fast-Tracked ... Minor Bleeding and was Well Tolerated When Given With ... a Schering-Plough Corporation (NYSE: SGP ) Phase ... receptor antagonist (TRA), were published today in The ...
Cached Medicine Technology:Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present its ... Get Up! Get Moving!®. This event promotes Hispanic family physical ... people of all ages and all sizes. The event, which ... at Kiest Park Recreation Center, 3080 S. Hampton Road, in ... 2007, we have partnered with National Alliance for Hispanic Health ...
(Date:9/2/2014)... September 02, 2014 West Hollywood ... complimentary consultations for Invisalign. This special offer includes a ... smiles to determine their candidacy for the procedure and ... Qualified patients may also be eligible for the Summer ... remainder of the month of August, patients who choose ...
(Date:9/2/2014)... 1, 2014 (HealthDay News) -- The quality of Americans, ... dietary disparity between the rich and poor is growing, ... most direct evidence to date that the extensive efforts ... quality are having some payoff, but it also indicates ... Dong Wang, a doctoral student in the department of ...
(Date:9/2/2014)... it comes to excess pounds and blood pressure, all fat ... The research found that belly fat -- the proverbial "spare ... more than overall body fat. It,s well known that ... wasn,t clear how the location of fat in the body ... Southwestern Medical Center in Dallas. Reporting Sept. 1 in ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 North ... America Resectoscopes Market Outlook to 2020? provides key ... The report provides value, in millions of US ... US dollars) within market segments –, ... (Disposable and Reusable) Electrodes and Bipolar (Disposable and ...
Breaking Medicine News(10 mins):Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4
... Legislation Introduced to Fund Lung Cancer ResearchBOSTON, Jan. ... Senator Susan Fargo (D-3rd Middlesex), the Senate Chair ... once again introducing comprehensive legislation that creates a ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO )"Now is the time for positive ...
... (Nasdaq: ROCM ) today announced that Covidien ... litigation which Rochester Medical,filed on March 16, 2004 against ... L.P.; Novation, LLC; VHA Inc.; and Premier Purchasing,Partners L.P. ... of the settlement, Rochester Medical, represented by The,Lanier Law ...
... festival in Park,City, Utah, usually known for power lunches, will ... full-service fitness center, called,the "G Gym." Actors Eliza Dushku ... of the many celebrities to snatch up appointments with top,Hollywood ... or $1,000 for,charity, up to $20,000. , ...
... YORK, Jan. 15 On Tuesday, February 3, 2009, ... The Fifth Annual Beyond Beauty Gala to benefit The ... genetic research and awareness for Obsessive-Compulsive Disorder (OCD). ... evening,s event will be held at The Union League ...
... Package and House Vote to Expand Child Health InsuranceTUCSON, Ariz., ... Corporation (Nasdaq: PRSC ) today provided an update ... package being sought by President-elect Barack Obama as well as ... insurance. The economic stimulus package under discussion includes aid ...
... Roxane Laboratories, Inc.,announced today the approval of their ... 500mg, 750mg, 1000mg, and Oral Solution,100mg/mL. The product ... nationwide. , Roxane Laboratories, ... UCB, Inc.,s KEPPRA(R) (levetiracetam). Annual sales of KEPPRA(R) ...
Cached Medicine News:Health News:Lung Cancer Alliance Hails Massachusetts State Senator for Taking Lead on Lung Cancer 2Health News:Celebrities Stay Fit at First Ever Full-Service Luxury Gym at Film Festival in Park City, Utah 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 3Health News:Providence Service Corporation Provides Update on Potential Medicaid 2Health News:Providence Service Corporation Provides Update on Potential Medicaid 3Health News:Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution 2
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
Multi-frequency, Super High Density, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path....
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
This versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Medicine Products: